Remove Life Science Remove Protein Remove RNA
article thumbnail

Key Trends in the Life Sciences to Look Forward to in 2022

XTalks

If the past year is anything to go by, then 2022 will also be a year marked by continued innovations in the life sciences. Here is a look at some life science trends to expect in the coming year, including key themes and topics in the pharmaceutical, biotechnology and medical device industries to keep an eye out for in 2022.

article thumbnail

Amvuttra RNAi Therapeutic Wins FDA Approval for Rare Genetic Protein Disorder

XTalks

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Silent Mutations That Gave Coronavirus a Selective Advantage

XTalks

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. The researchers focused on the spike proteins that protrude from the surface of the coronavirus, which are responsible for viral attachment and entry into host cells.

RNA 98
article thumbnail

Sanofi’s Qfitlia Gets FDA Approval as First siRNA Therapy for Hemophilia

XTalks

Through RNA silencing, it targets the expression of antithrombin, a protein that inhibits blood clotting. Qfitlia is the second RNA interference therapy to receive a highly anticipated FDA approval recently. The frequent intravenous infusions can be challenging for patients.

article thumbnail

Lab to jab in 100 days: manufacturing flexibility for future rapid responses

Pharmaceutical Technology

The mission was first put forward during the UK’s G7 Presidency of June 2021, with support from representatives of the life sciences industry. Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. The UK Government is behind this effort.

article thumbnail

World’s First RSV Vaccine + First Novel Treatment for ALS – Xtalks Life Science Podcast Ep. 109

XTalks

The treatment, an antisense oligonucleotide developed by Biogen, targets abnormal proteins arising from SOD1 mutations, which are associated with the development of ALS in some patients. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

article thumbnail

Wainua (Eplontersen) Now FDA-Approved for Rare Disease ATTRv-PN

XTalks

In individuals affected by ATTR, which includes both hereditary and wild-type (non-hereditary) variants, the TTR protein forms fibrils that accumulate in various tissues. These tissues comprise peripheral nerves, the heart, gastrointestinal system, eyes, kidneys, central nervous system, thyroid and bone marrow.